Seminari "Extending PARPi targeting HR defects into early breast cancer through OlympiA and understanding and tackling clinical resistance when PARPi fail" Dr. Andrew Tutt

 Seminaris
  Online —
08/07/2022
08/07/2022 -- From 12:00h to 13:00h
Organize :
VHIO (Vall d'Hebron Institut d'Oncologia)
Modality: Online
Share it:
Dr. Tutt

Speaker: Andrew Tutt, Head of the Division of Breast Cancer Research and Director of the Breast Cancer Now Toby Robins Research Centre at the ICR, London Talk 

Host: Violeta Serra / Judith Balmaña

Professor Tutt has developed a translational laboratory for triple negative breast cancer. He leads a clinical trial programme focusing on TNBC and cancers associated with functional deficiencies in BRCA1 and BRCA2.

He also leads translational laboratories at both the ICR and KCL, studying BRCA1 and BRCA2 associated TNBC forms of breast cancer. Andrew’s group publishes in high impact journals regularly and amongst their latest work they published a new TNBC target, PIM1 kinase, in Nature Medicine in November 2016.

He is Chief Investigator for the recently reported multicentre UKCRN ”Triple Negative Trial” and is Global Study Chair of the ‘OlympiA’ study – an adjuvant PARP inhibitor trial in patients with germline BRCA 1/2 mutations and breast cancer.

He has been a Visiting Professor at British Columbia Cancer Agency, Jean Lubrano Visiting Scholar at Harvard Medical School, and is a member of the St Gallen Early Breast Cancer International Consensus Panel and recently received the Addarii Award for his work in the field of breast and ovarian cancer research.

 

Inscriu-t'hi 

Subscribe to our newsletters and be a part of Campus Life

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.
Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).
Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.
Legal basis: Consent of the data subject.
Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.
Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.
Source: The data subject.
Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.